Pfizer Remains Confident in Lyme Vaccine Despite Missing Primary Endpoint

Pfizer and Valneva report ~75% efficacy for their Lyme disease vaccine in Phase 3 trials, despite missing the primary endpoint. Learn what this means for approval and future impact.